Man Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-58,768
| Closed | -$586K | – | 2339 |
|
|
2025
Q2 | $586K | Buy |
58,768
+36,236
| +161% | +$292K | ﹤0.01% | 1781 |
|
|
2025
Q1 | $135K | Sell |
22,532
-6,637
| -23% | -$48.7K | ﹤0.01% | 2090 |
|
|
2024
Q4 | $224K | Buy |
29,169
+7,516
| +35% | +$64.6K | ﹤0.01% | 1849 |
|
|
2024
Q3 | $221K | Buy |
+21,653
| New | +$330K | ﹤0.01% | 1834 |
|
|
2024
Q1 | – | Sell |
-10,005
| Closed | -$110K | – | 2194 |
|
|
2023
Q4 | $110K | Buy |
+10,005
| New | +$99.2K | ﹤0.01% | 1974 |
|
|
2023
Q1 | – | Sell |
-85,756
| Closed | -$1.67M | – | 2159 |
|
|
2022
Q4 | $1.67M | Sell |
85,756
-30,823
| -26% | -$602K | 0.01% | 1162 |
|
|
2022
Q3 | $2.22M | Buy |
+116,579
| New | +$2.69M | 0.01% | 1029 |
|
|
2022
Q2 | – | Sell |
-117,586
| Closed | -$2.79M | – | 994 |
|
|
2022
Q1 | $3.78M | Buy |
117,586
+97,985
| +500% | +$3.56M | 0.01% | 1010 |
|
|
2021
Q4 | $913K | Sell |
19,601
-7,301
| -27% | -$243K | ﹤0.01% | 1355 |
|
|
2021
Q3 | $726K | Buy |
26,902
+3,624
| +16% | +$94.7K | ﹤0.01% | 1447 |
|
|
2021
Q2 | $597K | Sell |
23,278
-1,925
| -8% | -$45.9K | ﹤0.01% | 1510 |
|
|
2021
Q1 | $861K | Sell |
25,203
-2,701
| -10% | -$97.6K | ﹤0.01% | 1328 |
|
|
2020
Q4 | $944K | Sell |
27,904
-12,519
| -31% | -$331K | ﹤0.01% | 1434 |
|
|
2020
Q3 | $997K | Buy |
+40,423
| New | +$1.09M | ﹤0.01% | 1373 |
|
Other funds holding ITOS
Man Group's ITOS Position: Q3 2025 in Review
Man Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 58,768 shares — an estimated $586K sold.
Man Group first reported a position in ITOS in Q3 2020 and held it in 14 quarters. The position peaked at $3.78M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Man Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Man Group sold 58,768 iTeos Therapeutics shares in Q3 2025, an estimated $586K.
- Man Group first reported a position in iTeos Therapeutics in Q3 2020 and held it in 14 quarters.
- Man Group's iTeos Therapeutics position peaked at $3.78M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.